Scribe Therapeutics Inc. (SCTX) News
Follow Scribe Therapeutics Inc. (SCTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
HC Wainwright maintains Scribe Therapeutics $60 share price target
Scribe Therapeutics’ price target was maintained by HC Wainwright & Co. at $60.00 per share, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 11:24 AM UTC
M
SCTX CRISPR therapies show promise for cardiovascular prevention
SCTX’s novel CRISPR-based platform for cardiovascular and metabolic diseases is advancing, with lead programs targeting LDL-C, Lp(a) and triglycerides. Early data point to durable efficacy and safety, backed by major par
EQUITY | Sep 02, 2026, 08:38 PM UTC
L
Scribe Therapeutics posts second-quarter revenue of $1.92 million, EPS $(2.62)
Scribe Therapeutics reported second-quarter 2026 revenue of $1.92 million and a net loss attributable to common stockholders of $6.48 million, or diluted loss per share of $(2.62).
EARNINGS | Sep 02, 2026, 08:33 PM UTC
L
SCTX raises $155.5M, starts STX-1150 first-in-human trial
SCTX initiated first-in-human trial for STX-1150, secured $155.5M via IPO/private placement, and received $25M+ in CIRM grants. Q2 2026 net loss narrowed to $6.5M on lower R&D expenses, with funding runway into H1 2029.
EARNINGS | Sep 02, 2026, 08:15 PM UTC
L
Scribe Therapeutics posts Q2 2026 $1.9M collaboration revenue, $6.5M net loss
Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9 million and a net loss of $6.5 million, or $2.62 per basic and diluted share. Cash, cash equivalents and marketable securities were $43.0 million as of J
EARNINGS | Sep 02, 2026, 08:14 PM UTC
L
Scribe Therapeutics 2Q revenue $1.92M
Scribe Therapeutics 2Q revenue was $1.92M.
EQUITY | Sep 02, 2026, 08:12 PM UTC
L
Scribe Therapeutics reports Q2 2026 financial results
Scribe Therapeutics (SCTX) reported its second-quarter 2026 financial results and recent corporate highlights.
EARNINGS | Sep 02, 2026, 08:08 PM UTC
L
Scribe Therapeutics to participate in upcoming investor conferences
Scribe Therapeutics (SCTX) will participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
H
Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront and early momentum beh
MNA | Jul 27, 2026, 03:21 PM UTC
H
Scribe Therapeutics 8.58M share IPO priced at $15.00
The deal guidance is...
EARNINGS | Jul 24, 2026, 10:05 AM UTC